INNATE PHARMA SP.ADR/1 (IDDA) - Total Liabilities
Based on the latest financial reports, INNATE PHARMA SP.ADR/1 (IDDA) has total liabilities worth €84.42 Million EUR (≈ $98.70 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore INNATE PHARMA SP.ADR/1 long-term investment allocation to see how much of total assets are deployed in long-term investments.
INNATE PHARMA SP.ADR/1 - Total Liabilities Trend (2021–2025)
This chart illustrates how INNATE PHARMA SP.ADR/1's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of INNATE PHARMA SP.ADR/1.
INNATE PHARMA SP.ADR/1 Competitors by Total Liabilities
The table below lists competitors of INNATE PHARMA SP.ADR/1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Faze Three Limited
NSE:FAZE3Q
|
India | Rs3.29 Billion |
|
Humanica Public Company Limited
BK:HUMAN
|
Thailand | ฿553.69 Million |
|
Winchester Bancorp, Inc. Common Stock
NASDAQ:WSBK
|
USA | $975.42 Million |
|
Gabelli Global Utility & Income Tr
NYSE MKT:GLU
|
USA | $291.78K |
|
Daishin Securities Co Ltd Pref 2
KO:003547
|
Korea | ₩38.04 Trillion |
|
Leap Therapeutics Inc
NASDAQ:LPTX
|
USA | $8.70 Million |
|
Kuang Hong Arts Management
TWO:6596
|
Taiwan | NT$969.97 Million |
|
Solteam Electronics Co Ltd
TWO:3484
|
Taiwan | NT$2.04 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down INNATE PHARMA SP.ADR/1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See INNATE PHARMA SP.ADR/1 net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how INNATE PHARMA SP.ADR/1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for INNATE PHARMA SP.ADR/1 (2021–2025)
The table below shows the annual total liabilities of INNATE PHARMA SP.ADR/1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €84.42 Million ≈ $98.70 Million |
-17.41% |
| 2024-12-31 | €102.22 Million ≈ $119.51 Million |
-17.08% |
| 2023-12-31 | €123.29 Million ≈ $144.13 Million |
-15.06% |
| 2022-12-31 | €145.14 Million ≈ $169.69 Million |
-9.32% |
| 2021-12-31 | €160.06 Million ≈ $187.12 Million |
-- |
About INNATE PHARMA SP.ADR/1
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Mo… Read more